Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>Genmab is a leader in antibody therapeutics, with a business model centered on its proprietary technology platforms (e.g., DuoBody®, HexaBody®) to develop a pipeline of innovative cancer treatments.</li>
  <li>The company's financial strength is historically rooted in high-margin royalties from its blockbuster drug DARZALEX (daratumumab), partnered with Johnson &amp; Johnson. However, it is strategically shifting towards co-owned and wholly-owned assets to diversify and secure long-term growth.</li>
  <li>Future growth hinges on the successful commercialization of its late-stage pipeline, including EPKINLY® (epcoritamab) and newly acquired assets, to mitigate the risk of revenue concentration and the eventual patent expiration of DARZALEX.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Genmab is a leader in antibody therapeutics, with a business model centered on its proprietary technology platforms (e.g., DuoBody®, HexaBody®) to develop a pipeline of innovative cancer treatments.
  The company's financial strength is historically rooted in high-margin royalties from its blockbuster drug DARZALEX (daratumumab), partnered with Johnson &amp; Johnson. However, it is strategically shifting towards co-owned and wholly-owned assets to diversify and secure long-term growth.
  Future growth hinges on the successful commercialization of its late-stage pipeline, including EPKINLY® (epcoritamab) and newly acquired assets, to mitigate the risk of revenue concentration and the eventual patent expiration of DARZALEX.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Denmark

Genmab A/S operates as a biotechnology company. The Company specializes in development of antibody therapeutics for the treatment of cancer. Genmab serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Genmab A/S (GMAB US)

Primer: Genmab A/S (GMAB US) - May 2026

Genmab is a leader in antibody therapeutics, with a business model centered on its proprietary technology platforms (e.g., DuoBody®, HexaBody®)...

αSK Primers

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)